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Abstract
Introduction: Objectives were to investigate whether interactions between human osteoarthritic chondrocytes and
4-hydroxynonenal (HNE)-modified type II collagen (Col II) affect cell phenotype and functions and to determine the
protective role of carnosine (CAR) treatment in preventing these effects.
Methods: Human Col II was treated with HNE at different molar ratios (MR) (1:20 to 1:200; Col II:HNE). Articular
chondrocytes were seeded in HNE/Col II adduct-coated plates and incubated for 48 hours. Cell morphology was
studied by phase-contrast and confocal microscopy. Adhesion molecules such as intercellular adhesion molecule-1
(ICAM-1) and a1b1 integrin at protein and mRNA levels were quantified by Western blotting, flow cytometry and
real-time reverse transcription-polymerase chain reaction. Cell death, caspases activity, prostaglandin E2 (PGE2),
metalloproteinase-13 (MMP-13), mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-B)
were assessed by commercial kits. Col II, cyclooxygenase-2 (COX-2), MAPK, NF-B-p65 levels were analyzed by
Western blotting. The formation of a1b1 integrin-focal adhesion kinase (FAK) complex was revealed by
immunoprecipitation.
Results: Col II modification by HNE at MR approximately 1:20, strongly induced ICAM-1, a1b1 integrin and MMP-13
expression as well as extracellular signal-regulated kinases 1 and 2 (ERK
1/2) and NF-B-p65 phosphorylation without
impacting cell adhesion and viability or Col II expression. However, Col II modification with HNE at MR
approximately 1:200, altered chondrocyte adhesion by evoking cell death and caspase-3 activity. It inhibited a1b1
integrin and Col II expression as well as ERK
1/2 and NF-B-p65 phosphorylation, but, in contrast, markedly elicited
PGE2 release, COX-2 expression and p38 MAPK phosphorylation. Immunoprecipitation assay revealed the
involvement of FAK in cell-matrix interactions through the formation of a1b1 integrin-FAK complex. Moreover, the
modification of Col II by HNE at a 1:20 or approximately 1:200 MR affects parameters of the cell shape. All these
effects were prevented by CAR, an HNE-trapping drug.
Conclusions: Our novel findings indicate that HNE-binding to Col II results in multiple abnormalities of
chondrocyte phenotype and function, suggesting its contribution in osteoarthritis development. CAR was shown to
be an efficient HNE-snaring agent capable of counteracting these outcomes.
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Articular cartilage is composed of chondrocytes embedded
in an exquisitely-organized extracellular matrix (ECM) of
collagen and proteoglycans. Chondrocytes, responsible for
regenerating and maintaining cartilage, exist in a rela-
tively-isolated environment, since this tissue lacks blood
vessels, lymphatic structures and nerves [1]. The ECM is
an important pleiotropic regulator of several fundamental
cellular processes, such as migration, proliferation, and
phenotypic expression [2]. Chondrocyte phenotype and
function are partially controlled by their interactions with
the surrounding ECM. These regulatory effects of ECM
are mediated through cell surface “adhesion receptors”
that support the attachment of cells to ECM molecules
both in vivo and in vitro. At the cell surface, matrix recep-
tors link the ECM to the cell interior through elements
of the cytoskeleton and other component proteins of
signal transduction pathways. In chondrocytes, the best-
described families of cell surface receptors are the integ-
rins as well as non-integrin receptors, including CD44 of
the hyaluronan-binding protein family, annexin V, and
intercellular adhesion molecule-1 (ICAM-1) [3,4]. Integrin
attachment stimulates the formation of focal adhesion
complexes, intracellular protein complexes that transduce
signals from the ECM to intracellular effectors, such as the
cytoskeleton [5]. Such receptors convey information from
the ECM to the intracellular compartment, utilizing sev-
eral signal transduction pathways. The binding of matrix
components to cell surface receptors also establishes a
pericellular pool of ECM molecules that may stabilize cell
phenotype.
Osteoarthritis (OA), a chronic disorder affecting the
elderly, is characterized by joint pain and disability. Dete-
rioration of articular cartilage is a hallmark of OA patho-
genesis [6]. Although the precise aetiology of this disease
is still unknown, it is clear that the degradation of articu-
lar cartilage is mediated by various factors, such as the
production of metalloproteinases (MMPs) and other pro-
ducts resulting from cellular activity that selectively
impact the cartilage matrix [7,8]. Among them, lipid per-
oxidation (LPO) end-products, such as 4-hydroxynonenal
(HNE) and malondialdehyde (MDA), are believed to play
key roles in cartilage damage in OA [9]. Our previous
study demonstrated, for the first time, that HNE level
was significantly higher in synovial fluids and osteoblasts
from OA patients than in normal subjects. We also
reported that free HNE was capable of inducing catabolic
and inflammatory responses in isolated OA chondrocytes
and altering the cellular phenotype of OA osteoblasts.
These responses were mediated by the modulation of a
panoply of signalling pathways, including mitogen-acti-
vated protein kinases (MAPKs) and nuclear factor-kappa
B( N F - B) [10-12]. Generally, free HNE most likely
represents one of the main LPO products that can modu-
late physiological as well as pathological processes, as
depicted in a recent, dedicated review [13].
Furthermore, the relevance of LPO products to OA
pathogenesis was manifested by their ability to form
adducts. By binding to proteins, HNE is capable of acti-
vating MMP-13 and increasing the susceptibility of type
II collagen (Col II) to proteolytic cleavage by MMP-13
[10]. The formation of HNE/Col II was augmented in
human cartilage treated with tumour necrosis factor-
alpha (TNFa and free radical donors. Tiku et al. reported
that chondrocyte-derived LPO products mediate the oxi-
dation of cartilage collagens [14]. They proposed that
oxidative modification of cartilage collagen by aldehyde
in vivo could result in alteration of the biochemical and
biophysical properties of cartilage collagen fibrils, making
them prone to degradation and initiating the changes
observed in aging and OA.
The present study was undertaken to clarify the signifi-
cance of high levels of HNE-Col II adducts in OA carti-
lage. We established that interactions between OA
chondrocytes and HNE-modified ECM protein (for exam-
ple, Col II) induced changes in cell phenotype and func-
tion, consequently contributing to cartilage damage seen
during OA development. The beneficial effect of carnosine
(CAR), an HNE-trapping drug, was also investigated.
Materials and methods
Specimen selection and chondrocyte culture
Post-surgery discarded human OA articular cartilage was
obtained from OA patients (aged 67 ± 9 years mean ±
SD, n = 27) who underwent total knee arthroplasty.
Informed consent had been obtained from patients with
OA for the use of their tissues for research purposes. All
patients were evaluated by rheumatologists who followed
American College of Rheumatology criteria [15]. The
experimental protocols and use of human tissues were
approved by the Research Ethics Board of Hôpital du
Sacré-Cœur de Montréal.
OA knee cartilage specimens were spliced and rinsed,
and chondrocytes were extracted by sequential enzymatic
digestion, as described previously [10]. Cartilage samples
were digested with 1 mg/ml of pronase (Sigma-Aldrich,
Oakville, ON, Canada) for one hour at 37°C, followed by
2 mg/ml of type IV collagenase (Sigma-Aldrich) for six
hours in Dulbecco’s modified Eagle’sm e d i u m( I n v i t r o -
gen, Burlington, ON, Canada) supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Invitrogen),
100 units/ml of penicillin and 100 μg/ml of streptomycin
(Invitrogen). The cells were seeded at high density in cul-
ture flasks at 37°C in a humidified atmosphere of 5%
CO2/95% air until they were confluent and ready for
experimentation.
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Human Col II (Sigma-Aldrich) was modified with HNE
(Cayman Chemical Company, Ann Arbor, Ml, USA) at
different molar ratios (MR) (1:20 to 1:200; Col II:HNE).
24-well plates (for cell suspensions) were coated with
0.1 mg/ml HNE-Col II adducts and incubated for 24 h
at 4°C. They were washed three times with phosphate-
buffered saline (PBS) to eliminate free HNE and con-
served at 4°C until used. First-passage chondrocytes
were distributed into pre-treated 24-well plates, as out-
lined above, at concentrations of 2 × 10
5 cells/cm
2 in
1 ml in DMEM containing 2% FBS, and incubated at
37°C for 48 h in a humidified atmosphere containing 5%
CO2/95% air.
Cell morphology and viability
Changes in cell morphology were studied by phase-con-
trast microscopy with a ×20/40 objective after hematox-
ylin and eosin staining (n = 5). Chondrocyte viability
was evaluated as described previously [16] using 3-(4,5-
dimethyl-thiazoyl)-2,5-diphenyl-SH-tetrazolium bromide
(MTT) assay in 96-well plates (Fisher Scientific Com-
pany, Ottawa, ON, Canada) by incubating them with
0.5 mg/ml MTT reagent (Sigma-Aldrich) for 15 minutes
at 37°C. Then, 100 μL of solubilization solution (0.04 M
HCl-isopropanol) was added, formazan salt was dis-
solved, and absorbance was read at 570 nm with the
micro-ELISA Vmax photometer (Bio-Tek Instruments,
Winooski, VT, USA).
Cell spreading assays
Chondrocytes were grown for 48 h in eight-well LabTeck
chambers (2 × 10
5 cells/cm
2)c o a t e dw i t h0 . 1m g / m l
HNE-Col II adducts. Cells were fixed by 4% paraformal-
dehyde for 30 minutes. An immunofluorescence was per-
formed and the areas, perimeters, Feret’sd i a m e t e r sa n d
circularity index of more than 200 cells were analyzed
using the threshold function of Image-J software (NIH)
(n = 4 for each condition).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde, permeabi-
lized with 0.2% Triton X-100 (Sigma-Aldrich) in PBS
and blocked in PBS-1% BSA (United States Biological,
Swampscott, MA, USA), and then incubated with Alexa
Fluor 488 Phalloidin (1:200 dilution, Invitrogen) for 30
minutes. After one wash in Tween 0.2% (Sigma-Aldrich)
in PBS and three in PBS alone, the chambers slides
were mounted with coverslips using Slow Fade® Gold
antifade reagent with DAPI mounting medium (Invitro-
gen). Fluorescence images were captured with a Zeiss
LSM710 confocal microscope, and the quantitative cell
morphology analysis was performed using images taken
with a Leica DM6000 epifluorescence microscope
(Deerfield, IL, USA) equipped with a Retiga EXi (QIma-
ging, Burnaby, BC, Canada) camera (n = 4).
Immunoprecipitation
To demonstrate the involvement of FAK in cell-collagen
interaction, OA chondrocytes (approximately 10
6 cells,
n = 3) were incubated for 48 h in HNE/Col II adducts-
coated plates. Then, cells were lysed on ice in 1 ml lysis
buffer (KLB: 40 mM Tris (pH 8.0), 250 mM NaCl, 0.1%
Nonidet P-40, 5 mM EDTA, 5 mM EGTA, 10 mM
b-glycerophosphate, 10 mM NaF, 0.3 mM Na3VO4,
1 mM DTT) supplemented with protease inhibitors
cocktail as described previously [11]. A total of 100 μg
of total protein was subjected to immunoprecipitation
with 1 μgo fm o u s ea n t i - h u m a na1b1 integrin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) in KLB buf-
fer containing 0.5 M NaCl for overnight at 4°C and then
for an additional two hours with protein A (Santa Cruz
Biotechnology). The resin was washed with KLB buffer
and proteins were removed from the resin by the addi-
tion of 50 μl undiluted SDS-loading buffer. The immu-
noprecipitates were analyzed by Western blotting using
mouse anti-human a1b1 integrin (Santa Cruz Biotech-
n o l o g y )o rr a b b i ta n t i - p F A Kantibody (Millipore, Etobi-
coke, ON, Canada), as primary antibody.
Measurement of caspase activities
Enzymatic caspase-3/8 activities were measured with
commercial kits. To measure caspase-8 activity, the cells
(n = 5) were washed with PBS and resuspended in
100 μL of lysis buffer (R&D Systems, Minneapolis, MN,
USA), left on ice for 10 minutes, and centrifuged. Pro-
tein concentration of the supernatants was measured
according to the bicinchoninic acid method (Pierce,
Rockford, IL, USA). Total proteins (50 μg) were reacted
with 200 μMI E T D - pNA substrate in the presence of
100 μL of reaction buffer. To quantitate caspase-3 activ-
ity, the cells were washed with PBS and lysed in 100 μL
of lysis buffer (Sigma-Aldrich), left on ice for 15 min-
utes, and centrifuged. Total proteins (5 μg) were reacted
with 200 μMD E V D - pNA substrate in the presence of
100 μL of reaction buffer. After 16 hours of incubation
at 37°C, p-nitroanilide release was measured at 405 nm
for caspase-3 and -8.
Protein detection by Western blotting
As u mo f2 0μg of total proteins from chondrocyte
lysates (n = 4) treated under the indicated conditions was
loaded for discontinuous 4 to 12% sodium dodecyl sul-
fate-polyacrylamide gel electr o p h o r e s i s .T h e yw e r et h e n
transferred electrophoretically onto nitrocellulose mem-
branes (Bio-Rad Laboratories, Mississauga, ON, Canada)
for protein immunodetection and semi-quantitative mea-
surement [10]. The primary antibodies used were mouse
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anti-human b-actin (Santa Cruz Biotechnology), anti-Col
II (Oncogene Research Products, La Jolla, CA, USA) or
rabbit anti-human COX-2 (Cayman Chemical Company),
anti-pFAK (Millipore), anti-total and phosphorylated
extracellular signal-regulated kinases 1 and 2 (ERK
1/2),
p38 MAPK, and NF-B-p65 (Cell Signaling Technology,
Inc., Danvers, MA, USA). After serial washes, the primary
antibodies were revealed by goat anti-mouse or anti-
rabbit IgG conjugated to horseradish peroxidase (Cell
Signaling Technology). Immunoreactive proteins were
detected with SuperSignal blotting substrate (Pierce) and
exposed to Kodak X-Omat film (Eastman Kodak Com-
pany, Rochester, NY, USA).
Prostaglandin E2 (PGE2) and MMP-13 determination
After incubating the chondrocytes for 48 h in collagen-
coated plates, the medium was collected, and PGE2 and
MMP-13 levels were assessedb ye n z y m ei m m u n o a s s a y
(Cayman Chemical Company) and ELISA kits (R&D
Systems). Detection sensitivity was 9 and 8 pg/ml,
respectively. All assays were performed in duplicate (n =
6). Absorbance was measured with the micro-ELISA
Vmax photometer (Bio-Tek Instruments).
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was isolated with TRIzol reagent according
to the manufacturer’s instructions (Invitrogen). RNA was
quantitated with RiboGreen RNA quantitation kits
(Molecular Probes, Eugene, OR, USA), dissolved in
diethylpyrocarbonate-treated H2O ,a n ds t o r e da t- 8 0 ° C
until used. One μg of total RNA was reverse-transcribed
with Moloney murine leukemia virus reverse transcrip-
tase (Fermentas, Burlington, ON, Canada), as detailed in
the manufacturer’s guidelines. One-fiftieth of the reverse
transcriptase reaction product was analyzed by real-time
quantitative PCR. The following specific sense and anti-
sense primers were purchased from Bio-Corp Inc. (Mon-
treal, QC, Canada): human ICAM-1, 5’-CCT ATG GCA
ACG ACT CCT TC-3’ (forward) and 5’-TGC GGT CAC
ACT GAC TGA G-3’ (reverse); human a1 integrin,
5’-GGA GCA ATT CGA CGA GCA CT-3’ (forward) and
5’-TTC ATC CCG CAG ATA CGC TA-3’ (reverse);
human b1 integrin, 5’-TTC AAT GCC ACC TGC CTC
AA-3’ (forward) and 5’-TTG GCC TCA ATG CTG AAG
CTC-3’ (reverse); human GAPDH, 5’-CAG AAC ATC
ATC CCT GCC TCT-3’ (forward) and 5’GCT TGA CAA
AGT GGT CGT TGA G-3’ (reverse); human MMP-13,
5’-CTT AGA GGT GAC TGG CAA AC (forward) and
5’-GCC CAT CAA ATG GGT AGA AG (reverse);
human COX-2, 5’-TTC AAA TGA GAT TGT GGG
AAA ATT GCT-3’ (forward) and 5’-AGT TCA TCT
CTG CCT GAG TAT CTT-3’ (reverse).
Quantitative PCR analysis was performed in a total
volume of 50 μl containing template DNA, 200 nM
sense and antisense primers, 25 μl of SYBR Green Mas-
ter Mix (Qiagen, Mississauga, Ontario, Canada), and 0.5
units of uracil-N-glycosylase (UNG, Epicentre Technolo-
g i e s ,M a d i s o n ,W I ,U S A ) .A f t e ri n c u b a t i o na t5 0 ° Cf o r
two minutes (UNG reaction) and at 95°C for 10 minutes
(UNG inactivation and activation of AmpliTaq Gold
enzyme), the mixtures were subjected to 40 amplifica-
tion cycles (15 s at 95°C for denaturation and one min-
ute at 60°C for annealing and extension). Incorporation
of SYBR Green dye into the PCR products was moni-
tored in real-time with a Mx3000 real-time PCR system
(Stratagen, La Jolla, CA, USA), allowing determination
of the threshold cycle (Ct) at which exponential amplifi-
cation of PCR products begins. After PCR, dissociation
curves were generated with one peak, indicating amplifi-
cation specificity. A Ct value was obtained from each
amplification curve with software provided by the man-
ufacturer (Stratagen).
Relative mRNA expression in chondrocytes was quanti-
fied according to the ΔΔCt method, as detailed in the
manufacturer’s( S t r a t a g e n ’s) guidelines. A ΔCt value was
calculated, first by subtracting the Ct value for the house-
keeping gene GAPDH from the Ct value for each sample.
A ΔΔCt value was then calculated by subtracting the ΔCt
value for the control (unstimulated cells) from the ΔCt
value for each treatment. Fold changes compared to the
controls were then determined by 2
-ΔΔC
t.E a c hP C Rg e n -
erated only the expected specific amplicon, as shown by
melting temperature profiles of the final product and by
gel electrophoresis of the test PCRs. Each PCR was run
in triplicate on two separate occasions for each indepen-
dent experiment (n = 6).
Flow cytometric analysis
Incubated cells in unmodified or HNE-modified Col II
were trypsinized, centrifuged and then labeled with
either 1 μgo fap u r i f i e dm o u s eI g G 1 isotype control
(BD Biosciences PharMingen; San Diego, CA, USA), or
mouse anti-human ICAM-1 (15.2) (Santa Cruz Biotech-
nology) in PBS/2% FBS for 60 minutes at 4°C. The cells
were then washed twice in PBS and incubated with
Alexa Fluor® 488 goat anti-mouse IgG (Invitrogen)
diluted 1/500 in PBS/2% FCS, for 30 minutes at 4°C in
the dark. They were washed, re-suspended in 500 μlo f
PBS and analyzed. ICAM-1 surface expression on chon-
drocytes (n = 4) was assessed in a Coulter Epics XL
flow cytometer with Expo32 software (Beckman Coulter
System, Mississauga, ON, Canada).
MAPK and NF-B quantification
After 48 h of incubation, human OA chondrocytes (n =4 )
were lysed, and protein levels were quantitated according
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ELISA kits for total and phosphorylated p38 MAPK, ERK
1
(p44), ERK
2 (p42), and NF-B-p65 (Cell Signaling Tech-
nology, Inc.). The data are expressed as fold induction.
Statistical analysis
Results were expressed as the mean ± SEM. Statistical
differences between two groups of data were analyzed
using ANOVA test and Bonferroni’s multiple compari-
son procedures. A difference of less than or equal to
0.05 was considered significant.
Results
HNE-binding to Coll II induces changes in cell
morphology, viability and phenotype
To investigate the effect of HNE-binding to Col II on
chondrocyte function, we first documented changes in
cell morphology and viabilityb yp h a s e - c o n t r a s tm i c r o -
scopy and MTT assay, respectively. After 48 h of incu-
bation, Col II modification by HNE at high MR (1:200)
(Figure 1c) induced alterations in cell morphology com-
pared to unmodified Col II or collagen exposed to HNE
at low MR (1:20) (Figure 1a, b). The changes in cell
morphology were associated with cell viability decreased
by 30% and caspase-3 activity increased by approxi-
mately two-fold respectively (Figure 1d). In the same
pattern, caspase-8 activity was also increased (data not
shown). Thereafter, we evaluated the ability of HNE-
modified Col II to affect chondrocyte phenotype via Col
II protein expression. As illustrated in Figure 1e, Col II
protein expression was reduced by 25 and 65% when
the cells were seeded in Coll II treated with HNE at a
1:100 MR and 1:200 MR respectively, indicating altered
cell phenotype. Col II modification with HNE up to
1:100 MR did not influence cell viability, and caspase-3
activity. These data indicate that interactions between
human OA chondrocytes and HNE-Coll II adduct influ-
ence cell morphology, viability and phenotype.
Then, chondrocytes morphology were analysed by mea-
suring main parameters of the cell shape, including: the
area, Feret’s diameter, perimeter, and circularity index.
Figure 2a indicates that culture conditions don’ta f f e c tc e l l
area. However, Col II modification with HNE at a 1:200
MR significantly decreased the Feret’sd i a m e t e ro fc e l l
compared to the control. (Figure 2b), indicating that cells
make less straight membrane protrusions. Moreover, cell
perimeter is significantly increased when cells were cul-
tured in the presence of HNE-modified Col II at a 1:20
MR compared to the control (Figure 2c), but decreased in
t h ep r e s e n c eo fH N E - m o d i f i e dC o lI Ia ta1 : 2 0 0M R .I n
the same way, the circularity index of the cells is reduced
in the presence of HNE-modified Col II at a 1:20 MR and
increased then after in the presence of HNE-modified Col
II at a 1:200 MR (Figure 2d). Finally, cells seem to be more
spread in unmodified Col II or HNE-modified Col II at a
1:20 MR than in HNE-modified Col II at a 1:200 MR
(Figure 2e-g). Taken together, these results indicate that
cells are more rounded and smooth when Col II was high
alkylated by HNE when compared to unmodified Col II
and low alkylated Col II.
HNE-binding to Col II modulates the expression of
adhesion molecules (ICAM-1 and a1b1 integrin)
Cell adhesion molecules are expressed on the cell sur-
face and are involved in binding with other cells or with
the ECM components. They play a critical role in a
wide array of biological processes that include differen-
tiation, viability, inflammation and catabolism. In the
present study, we investigated both ICAM-1 and a1b1
integrin in cultured chondrocytes in HNE-modified Col
II-coated plates. Compared to unmodified Col II, Col II
modification with HNE at low MR (1:20) induced
ICAM-1 expression at the protein (Figure 3a) and
mRNA (Figure 3d) levels by 440 (P < 0.001) and 400%
(P < 0.001), respectively. No change in ICAM-1 expres-
sion was observed when Col II was modified by HNE at
a 1:100 or 1:200 MR.
We then undertook flow cytometric analysis to confirm
the Western blotting and real-time PCR data. Figure 3C
discloses that Col II modification by HNE at a 1:20 MR
(Figure 3c.b2) increased the percentage of cells expres-
sing ICAM-1 by two-fold at the surface of chondrocytes,
compared to control cells (Figure 3c.b1). When the data
were analyzed for X-mean fluorescence intensity, almost
a 10-fold increment in ICAM-1 expression was noted
(Figure 3c.b2). However, incubated cells with HNE-
treated Col II at a 1:200 MR presented ICAM-1 expres-
sion levels comparable to those in control cells in terms
of both cell percentage and X-mean fluorescence inten-
sity (Figure 3c.b3). Flow cytometry of ICAM-1 expression
on chondrocytes in response to their incubation in HNE-
modified Col II was in agreement with the Western blot-
ting and real-time PCR data.
Furthermore, a1a n db1 integrin expression increased,
in the same pattern, by 150 (P <0 . 0 5 )a n d1 6 0 %( P <0 . 0 5 )
at the protein level (Figure 3a) and by 230 (P < 0.05) and
310% (P < 0.01) at the mRNA level (Figure 3d) when Col
II was modified by HNE at a 1:20 MR. However, Col II
modification with HNE at a 1:200 MR dramatically
decreased the expression of both a1a n db1i n t e g r i nb y
approximately 85% (P < 0.001) at the protein and mRNA
levels (Figure 3a, d). Collectively, these data suggest that
inhibition of a1b1 integrin expression will be involved in
alterations of chondrocyte morphology, viability and phe-
notype, as observed in Figure 1.
Coimmunoprecipitation experiments were performed
to determine the involvement of FAK in cell-matrix
interactions. Our data showed that pFAK is detected in
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drocytes (Figure 3b). The phosphorylated level of FAK
increased when Col II was modified by HNE at a 1:20
MR and then decreased when Col II was modified by
HNE at a 1:200 MR.
Interactions between HNE-modified Col II and chondrocytes
induce inflammatory and catabolic responses
In the next series of experiments, we investigated
whether interactions between chondrocytes and their
surrounding matrix, HNE-modified Col II, regulate the
production of factors known to be involved in OA, such
as PGE2, a product of COX-2, and MMP-13. Our data
revealed that HNE-modified Col II induced PGE2 release
and COX-2 expression. PGE2 (Figure 4a) peaked at 720
pg/ml (P < 0.001), and COX-2 protein and mRNA
(Figure 4b, c) reached 480 and 350% (P < 0.001), respec-
tively, when Col II was treated with HNE at a 1:200 MR.
We additionally established that HNE-modified Col II
evoked a significant increase of MMP-13 but inversely
to COX-2. MMP-13 protein and mRNA (Figure 4d)
reached maximum levels of 17 ng/ml (P < 0.001) and
400% (P < 0.001), respectively, when Col II was modified
with HNE at a 1:20 MR. Taken together, these findings
Figure 1 HNE-binding to Coll II induces changes in chondrocytes morphology, viability and phenotype. Twenty-four-well plates were
coated with 0.1 mg/ml human Col II and treated after with HNE at different molar ratios (1:20 to 1:200; Col II:HNE). After several washes, human
OA chondrocytes were seeded at 2 × 10
5 cells/cm
2 and incubated up to 48 h. Cell morphology of cultured chondrocytes in untreated Col II (a),
HNE-treated Col II at a 1:20 MR (b), and HNE-treated Col II at a 1:200 MR (c) was observed by phase contrast microscopy after hematoxylin and
eosin staining (mag. 20 to 40×). (d) Cell viability and caspase-3 activity were determined with MTT assay and commercial kit respectively. (e) Col
II protein expression was analyzed in cellular extract by Western blot. ANOVA tests and Bonferroni’s multiple comparison were performed to
compare each condition. The data are means ± SEM of n =5 .*P < 0.05; **, P < 0.01.
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HNE-modified Col II may contribute to the production
of inflammatory and catabolic mediators known to be
involved in OA.
HNE-binding to Col II activates p38 MAPK, ERK
1/2 and
NF-B-p65
To gain insights into the signalling pathways activated
during interactions between chondrocytes and HNE-
modified Col II, we examined the HNE-induced phos-
phorylation patterns of MAPKs over extended time
periods by Western blotting and ELISA. As shown in
Figure 5a, b, our data indicate that p38 MAPK, ERK
1/2
and NF-B-p65 phosphorylation levels rose within 48 h of
stimulation and depended on Col II alkylation level. p38
MAPK activation peaked when Col II was modified by
HNE at 1:200 MR (Figure 5a, b.b1). In contrast, ERK
1/2
(Figure 5a, b.b2, b.b3) and NF-B-p65 (Figure 5a, b.b4)
Figure 2 Chondrocyte morphology analysis and actin cytoskeleton. Chondrocytes were incubated as described in Legend 1 and cell
morphology was analyzed by fluorescence microscopy using a phalloidin staining and ImageJ analysis. For each condition, the area (a), the Feret’s
diameter (b), the perimeter (c) and the circularity index (d) of more than 200 cells was measured. Cell cytoskeleton was observed by phalloidin in
cultured chondrocytes in untreated Col II (e), HNE-treated Col II at a 1:20 MR (f), and HNE-treated Col II at a 1:200 MR (g). Scale bar, 20 μm. ANOVA
tests and Bonferroni’s multiple comparison were performed to compare each condition. The data are means ± SEM of n =4 .* *P < 0.01; *** P < 0.001.
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Page 7 of 14Figure 3 HNE-modified Col II modulates adhesion molecules expression and focal adhesion kinase in human OA chondrocytes.C e l l s
were incubated as described in Legend 1 and protein (a) and mRNA (b) levels of ICAM-1 and a1b1 integrin were analyzed in cellular extracts
by Western blot and real-time RT-PCR, respectively. (b) a1b1 integrin antibody coimmunoprecipitates pFAK. One hundred micrograms of total
protein extracts of chondrocytes were immunoprecipitated with mouse anti-a1b1 integrin antibody. a1b1 immunoprecipitates were
immunoblotted with pFAK or a1b1 integrin antibody. (c) Protein expression of ICAM-1 was qualitatively evaluated by flow cytometry using
mouse anti-human ICAM-1 and Alexa FluoR 488 goat anti-mouse IgG. Mouse isotype IgG1 was used as a negative control. (b1) untreated Col II,
(b2) HNE-treated Col II at a 1:20 MR, (b3) HNE-treated Col II at a 1:200 MR. ANOVA tests and Bonferroni’s multiple comparison were performed to
compare each condition. The data are means ± SEM of n =5 .* P < 0.05, **P < 0.01, ***P < 0.001.
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Page 8 of 14activation peaked when Col II was exposed to HNE at a
1:20 MR HNE and declined gradually thereafter when Col
II was modified by HNE at a 1:100 or 1:200 MR. However,
our results disclosed that interactions between cells and
HNE-modified Col II evoked weak activation of c-Jun
N-terminal kinase 1/2 (JNK
1/2) (data not included).
CAR prevents HNE-modified Col II-induced chondrocyte
functions
To establish whether HNE-modified Col II induced
changes in cell morphology and function could be
potentially reversed by CAR, an HNE-trapping drug,
0.1 mM CAR was added to HNE-modified, Col
II-coated plates one hour before cell seeding, and differ-
ent factors were investigated. As seen in Figure 6, CAR
prevented changes in cell morphology (Figure 6c) when
compared to the untreated Col II (Figure 6a) and HNE-
modified Col II at a 1:200 MR (Figure 6b). CAR alone
had no effect on cell viability (Figure 6d). Interestingly,
we observed that cell mortality as well as PGE2 and
MMP-13 release were abolished by CAR (Figure 6e, f)
when cells were incubated with HNE-modified Col II.
These data indicated that CAR prevented changes in
chondrocyte phenotype and function by establishing
normal interactions between the cells and their sur-
rounding matrix.
Discussion
The main purpose of this study was to investigate inter-
actions between human OA chondrocytes and HNE-
modified Col II. When seeded in HNE-treated Coll II,
significant amendment of chondrocyte morphology,
from the typical chondrocyte-like polygon shape to
rounded, semi-detached cells, was observed; mainly
when Col II was modified by HNE at a 1:200 MR (Col
II:HNE). Since morphological changes in cell shape are
consistent with the induction of cell death, we studied
cell viability and extrinsic caspase-3 activity. Our data
disclosed that changes in cell morphology were accom-
panied by increased cell mortality, caspase-3 activation
and loss of cell phenotype, as determined by Col II
expression. Several authors have reported that fibroblast
and osteoblast interactions with MDA-collagen adducts
or advanced glycation end product (AGE)-modified col-
lagen affected both the morphology and proliferation of
these cells, leading to reduced cell adhesion, migration
and viability [17,18]. It has been proposed that changes
in both the physical properties and charge profiles of
protein are particularly important for the attachment of
cells to collagenous basement membranes. To determine
that chondrocyte morphology and phenotype were clo-
sely correlated with cell-matrix interactions through
adhesion molecules, we first investigated ICAM-1 and
a1b1 integrin expression. Our results clearly showed
that interactions between HNE-modified Coll II at a
1:20 MR and chondrocytes, probably through a1b1
receptors, significantly increased its own expression, and
Figure 4 Interactions between human OA chondrocytes and
HNE-modified Col II induced COX-2 and MMP-13 expression.
Cells were incubated as described in Legend 1 and culture media
was collected. PGE2 (a) and MMP-13 (d) release was assessed by
enzyme immunoassay and ELISA kits. Levels of COX-2 protein (b) as
well as COX-2 mRNA (c) and MMP-13 mRNA (d) were analyzed in
cellular extracts by Western blot and real-time RT-PCR, respectively.
ANOVA tests and Bonferroni’s multiple comparison were performed
to compare each condition. The data are means ± SEM of n =6 .* P
< 0.05, **P < 0.01, ***P < 0.001.
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Page 9 of 14Figure 5 Activation of MAPK and NF-B pathways by HNE-modified Col II in human OA chondrocytes. Cellular extracts from
incubated chondrocytes (see legend 1) were subjected to assess total and phospho-p38 MAPK, ERK
1 (p44), ERK
2 (p42) and NF-B-p65 by (a)
Western blot analysis using specific antibodies or by (b) ELISA procedure using commercial kit. (b1) p38 MAPK, (b2) ERK
1, (b3) ERK
2, (b4)
NF-B-p65. ANOVA tests and Bonferroni’s multiple comparison were performed to compare each condition. The data are means ± SEM of
n =4 .* P < 0.05, **P < 0.01, ***P < 0.001.
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Page 10 of 14Figure 6 Carnosine prevents HNE-modified Coll II-induced changes in chondrocytes phenotype and function. A total of 0.1 mM
carnosine was added to HNE-modified Col II-coated plates before cells seeding. Cell morphology of human OA chondrocytes was analysed by
phase-contrast microscopy. Cells were incubated in (a) untreated Col II, (b) HNE-treated Col II at a 1:200 MR, (c) HNE-treated Col II at a 1:200
MR + 0.1 mM CAR, (d) 0.1 mM CAR-treated Col II. (e) Cell viability of chondrocytes was evaluated by MTT assay. (f) Culture media from cultured
cells was used to determine PGE2 and MMP-13 levels. ANOVA tests and Bonferroni’s multiple comparison were performed to compare each
condition. The data are means ± SEM of n =4 .* P < 0.05, **P < 0.01, ***P < 0.001.
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Page 11 of 14was dramatically decreased thereafter when Col II was
modified by HNE at a 200 MR. However, ICAM-1
expression was significantly enhanced by HNE-treated
C o lI Ia ta1 : 2 0M Ra n dt h e nd e c l i n e dt ot h ec o n t r o l
level. Since Col II is a ligand for a1b1 integrin, we
suggest that the increment of ICAM-1 expression is
a1b1-dependent. The involvement of a1b1i n t e g r i ni n
ICAM-1 expression was proposed by Nakayamada et al.
[19], who postulated that the interaction of b1i n t e g r i n
with the ECM heightens ICAM-1 expression in synovial
cells. In OA, integrin and ICAM-1 receptors play a criti-
cal role in maintaining cartilage homeostasis [20]. High
ICAM-1 and a1b1 integrin expression levels in the early
stages of OA are indicated by several reports in humans
and animals [20-22]. In adult joints, increased of b1
integrin was reported in osteoarthritic monkey cartilage
compared to normal cartilage [22] and in human OA
samples at minimally damaged locations compared to
areas with more severe lesions [23]. Knee joints of
a1b1-null mice display precocious proteoglycans loss,
cartilage erosion associated with increased MMP-2 and
MMP-3 expression, and synovial hyperplasia [24,25].
Then after, we have used immunoprecipitation method
to examine the possibility that FAK participates in signal-
ing from a1b1 integrins after cell adhesion. We provide
evidence for formation of a a1b1 integrin-pFAK complex
in cultured chondrocytes. Moreover, we demonstrate that
the phosphorylated level of FAK decreased when cells
were incubated with HNE-modified Col II at a 1:200 MR.
These findings support the role of FAK as intermediates
in a1b1 integrin-dependent signaling in chondrocytes
adhering to HNE-Col II adducts. Our work, interpreted in
the context of what is known about focal adhesion assem-
bly, suggests that chondrocytes adhesion to HNE-Col II
adducts by a1b1 integrins leads to recruitment of FAK.
Intracellular signaling from the ECM is mediated through
major cell-surface receptors called integrins, which serve
as transmembrane links between the extracellular environ-
ment and focal adhesions within the cell [26]. Interaction
of integrins with the ECM at these focal adhesions leads to
recruitment of several signaling molecules such as paxillin,
vinculin, talin and FAK [27,28] Interaction between b1
integrin and Col II in chondrocytes protects cells against
apoptosis and mediates responses to external changes by
maintaining the tissue composition and mechanical prop-
erties of articular cartilage [5].
Previous reports have demonstrated that ECM modifi-
cation generates a panoply of signalling pathways impli-
cated in various physiological and pathophysiological
events [29]. To investigate this concept, we studied the
possibility that HNE-modified Col II modulates catabolic
and inflammatory responses known to be involved in OA
through MAPK and NF-B activation. Our data clearly
showed that low alkylation of Col II strongly activates
ERK
1/2 and NF-B-p65 and slightly activates p38 MAPK.
However, high alkylation of Col II dramatically inhibits
ERK
1/2 and NF-B-p65 and strongly stimulates p38
MAPK. Collectively, our findings suggest that NF-B/
ERK
1/2 and p38 kinase oppositely regulate cell viability
and adhesion in the presence of HNE-Col II adducts.
Integrins control cell adhesion, migration, and survival by
activating complex signalling networks that involve
MAPK members, such as ERK [30]. Previous studies with
human chondrocytes have determined that activation of
the b1 integrin and subsequent ERK
1/2 and NF-B signal-
ling pathways is extremely important for cell differentia-
tion and survival, and the inhibition of which can induce
apoptosis [31,32]. Stupack et al. [33] suggested that
“integrin-mediated death” is elicited by the cytoplasmic
domain of unligated b1-integrin, resulting in caspase-8
recruitment to the cell membrane. In contrast, Wei et al.
[34] found that p38 MAPK activity in chondrocytes is
essential for the induction of cell death. p38 MAPK
forms a complex with caspase-8 and consequently
attaches to the death-executing machinery.
Since OA is associated with cartilage degradation and
synovium inflammation, we investigated the ability of
HNE-Col II adducts to induce catabolic and inflamma-
tory genes. Among them, MMP-13 and COX-2 assumed
a crucial role. We found that interactions between chon-
drocytes and the HNE-modified matrix specifically
evoked MMP-13 by low Col II alkylation and COX-2 by
high Col II alkylation. These data, combined with those
on signalling pathways, suggest that MMP-13 and COX-
2 expression depend mainly on ERK
1/2 and p38 MAPK,
respectively. It has been reported that Col I and fibronec-
tin fragments induce MMP-13 expression in chondro-
cytes through ERK
1/2 signalling via a1b1a n davb3
integrin, respectively [5,35,36]. However, it has been
observed that integrin-mediated adhesion to ECM pro-
teins induces de COX-2 synthesis involving signalling
through the p38 MAPK pathway [37]. The role of AGE-
modified proteins in OA has been demonstrated in pre-
vious studies. It has been found that AGEs significantly
stimulate a panoply of signalling pathways-mediating
MMP-1, -3, and -13 expression [38-40]. These responses
occur through receptors for AGEs, implicating those
engaged in catabolic and inflammatory processes in OA.
Finally, we tested the hypothesis that CAR treatment
is capable of inhibiting HNE-Col II adduct-induced
changes in cell morphology and function. The data
revealed that 0.1 mM CAR prevents changes in cell
morphology and viability and blocked the production of
factors known to be involved in OA, such as MMP-13
and PGE2. CAR exerts its effect in a dose-dependent
manner with the maximum at 0.1 mM (data not
shown). CAR was previously found to directly trap HNE
[41]. By trapping HNE in stable covalent adducts, CAR
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Page 12 of 14can inhibit HNE-induced protein cross-linking. There-
fore, it has the ability to displace bound HNE off the
protein surface or to bind covalently into HNE-protein
adducts. It is noteworthy that CAR can be covalently
incorporated into glycated proteins, and consequently
reduce protein carbonyl content [42]. In addition, CAR
has been observed to reverse the physicochemical
changes of proteins induced by glycation [43]. CAR,
a dipeptide (b-alanyl-L-histidine), is considered to be
a natural antioxidant and antiglycating agent that
suppresses protein modifications by AGEs and LPO pro-
ducts [44,45]. It may play an important part as an anti-
aging molecule, since it can delay senescence in cultured
fibroblasts and reverse the senescent phenotype in cul-
tured human cells [46]. Furthermore, it is useful in pre-
venting several diseases, as beautifully depicted in a
recent, dedicated review [47].
Conclusions
Collectively, we presented evidence that Col II modifica-
tion by HNE is capable of inducing changes in chondro-
cyte phenotype and function. Our results clearly showed
that interactions between chondrocytes and HNE-Col II
adducts, probably via adhesion molecules, strongly evok-
ing a panoply of signalling pathways that trigger cell
adhesion and viability as well as MMP-13 and COX-2
expression, as illustrated in Figure 7. The fact that
HNE-Col II adducts elicited cell death and catabolic and
inflammatory responses suggested their involvement in
OA. CAR has been found to prevent the effects of
HNE-Col II adducts, although the mechanism of action
has not yet been elucidated. Further research is required
to understand the implication of Col II modification by
HNE and other ECM components in OA as well as the
potential of HNE-trapping drugs in OA.
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